KardiaAI vs PMcardio

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by AliveCor
VS
by Powerful Medical

AI Verdict

KardiaAI and PMcardio are direct competitors, both offering AI-powered ECG interpretation for cardiac condition detection. KardiaAI focuses on an API library for integration into other devices and mobile apps, detecting various cardiac conditions including AFib, bradycardia, and tachycardia, with recent FDA clearances expanding its detection capabilities to 39 cardiac determinations, including heart attack and ischemia. PMcardio, available as a mobile app and web platform, interprets ECGs for over 50 cardiac conditions, including STEMI/OMI and reduced LVEF, and offers visual AI explainability. While both are medical-grade AI solutions, KardiaAI emphasizes its FDA clearance and integration capabilities, whereas PMcardio highlights its broader diagnostic range, CE certification, and clinical validation in numerous studies, with FDA Breakthrough Device Designation for its STEMI AI ECG model.

Choose KardiaAI if…

Choose KardiaAI if you require an FDA-cleared AI software library for integration into existing mobile apps and web platforms, focusing on the detection of common cardiac conditions like AFib, bradycardia, and tachycardia from ambulatory ECG rhythms. It is particularly well-suited for developers and healthcare providers looking to embed medical-grade ECG analysis capabilities into their own systems for remote monitoring and telehealth services.

View KardiaAI →

Choose PMcardio if…

Choose PMcardio if you need a comprehensive, CE-certified AI platform for rapid and accurate interpretation of 12-lead ECGs, assessing over 50 cardiac conditions including critical findings like STEMI/OMI and reduced LVEF. This tool is ideal for clinicians at the point of care, including emergency medicine, internal medicine, and cardiology, who require instant, expert-level interpretations, visual AI explainability, and patient management recommendations, even from digitized images of old or poor-quality ECGs.

View PMcardio →

When choosing between KardiaAI and PMcardio, physicians should consider their primary use case and desired level of ECG interpretation depth. KardiaAI, an FDA-cleared AI software library by AliveCor, excels in analyzing ambulatory ECG rhythms for the detection of specific cardiac conditions such as AFib, bradycardia, and tachycardia. It is particularly well-suited for integration into existing mobile apps and web platforms, offering medical-grade accuracy for heart rhythm data and detecting a comprehensive set of 35 FDA-cleared determinations including various rhythms and morphologies. Physicians prioritizing continuous, remote monitoring and focused arrhythmia detection, especially those utilizing AliveCor’s personal ECG devices, may find KardiaAI’s subscription-based model and API library integration beneficial.

In contrast, PMcardio is a CE-certified AI platform that provides rapid and accurate interpretation of 12-lead ECGs to assess over 50 cardiac conditions. Its key practical difference lies in its broader diagnostic capabilities, including detection of STEMI/OMI, reduced LVEF, and conduction disorders, along with visual AI explainability through heatmaps. PMcardio also offers patient management recommendations based on European Society of Cardiology guidelines, which can be a significant advantage for point-of-care decision-making. With a freemium pricing model, including a free plan for up to 5 ECG analyses per month, PMcardio is ideal for clinicians who require comprehensive, expert-level ECG interpretation for a wider range of conditions and value features like AI explainability and guideline-adherent treatment suggestions.

Ultimately, a physician focused on integrating robust, FDA-cleared arrhythmia detection into a remote monitoring workflow would likely lean towards KardiaAI. However, for those needing a more expansive diagnostic tool for 12-lead ECGs, including acute events and structural heart disease screening, coupled with clinical decision support and visual explainability, PMcardio presents a compelling option.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature KardiaAI PMcardio
Pricing Subscription-based for integrated services Freemium
Deployment Software as a Medical Device (SaMD), API library integrated into mobile apps and web platforms Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
FDA Status 1 AI-estimated Pending AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers a mobile app and web platform, allowing for immediate use without IT integration, and supports various 12-lead ECG formats, including images of paper ECGs. KardiaAI, while integrated into mobile apps and web platforms, primarily functions as an API library, suggesting a less direct end-user experience for standalone use compared to PMcardio's dedicated applications. PMcardio's explainable AI with heatmaps also enhances user understanding of the diagnoses.

Clinical Value

PMcardio

PMcardio detects over 50 cardiac conditions, including advanced diagnoses like STEMI/OMI and reduced LVEF, and has demonstrated superior accuracy in clinical studies, including a 2x sensitivity for early STEMI detection and a 98.3% accuracy for atrial fibrillation. KardiaAI detects a more limited set of conditions, including AFib, bradycardia, tachycardia, and normal sinus rhythm, along with some PVC and QRS variations. While KardiaAI has FDA clearance for 35 cardiac determinations, PMcardio's broader diagnostic scope and strong clinical validation for critical conditions like OMI give it an edge.

Pricing & Value

PMcardio

PMcardio offers a transparent freemium model with a free plan for 5 ECG analyses per month, and clear pricing for individual, team, and organizational plans. KardiaAI uses a subscription-based model for integrated services, with specific monthly and annual costs for KardiaCare plans. [cite: Tool A JSON] PMcardio's freemium model provides immediate value and flexibility for individual clinicians to try the product before committing to a paid plan.

Enterprise Readiness

PMcardio

PMcardio is designed for enterprise deployment, offering integration with existing ECG systems, EHR/CVIS, and EMS systems, with robust security and compliance (SOC 2 Type II, ISO 27001, GDPR, HIPAA). It also provides enterprise-level functionalities like central report management and role-based access control. KardiaAI is an API library intended for integration into mobile apps and web platforms, and while it is HIPAA compliant and has a BAA, its enterprise features are not as explicitly detailed as PMcardio's. [cite: Tool A JSON, 15]

Innovation

PMcardio

PMcardio demonstrates significant innovation with its detection of over 50 ECG findings, including advanced features like Queen of Heartsu2122 for STEMI/OMI detection, LVsenseu2122 for reduced LVEF, and ECGxplainu2122 for visual AI explainability with heatmaps. It also boasts a strong research focus with over 25 clinical validation studies. While KardiaAI has FDA-cleared AI algorithms and has expanded its detection capabilities, PMcardio's specialized AI models for complex cardiac conditions and explainable AI features represent a more advanced innovative approach.

Support & Docs

Tie

Both tools offer documentation and support. PMcardio provides a help center with FAQs, tutorials, and instructions for use in multiple languages. AliveCor's KardiaAI, through its associated Kardia devices and app, offers a user manual, troubleshooting guides, and email support. Without more specific details on response times, comprehensiveness, or user satisfaction for their support channels, it is difficult to definitively choose a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature KardiaAI PMcardio
Name KardiaAI PMcardio
Company AliveCor Powerful Medical
Description FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately.
CE Certification Not specified 1
Key Detections Atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE) 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies)

Videos

Demos, reviews, and walkthroughs featuring KardiaAI and PMcardio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

KardiaAI is designed as an API library for integration into mobile apps and web platforms, and it can automatically pull ECGs into EHR systems, partnering with systems like GE Healthcare's MUSEu2122 NX. PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, allowing for seamless connection to existing ECG systems and communication tools, and can export detailed PDF reports for integration into EHRs. PMcardio also supports various ECG formats, including scanned or photographed 12-lead ECGs.
KardiaAI's FDA-cleared algorithms can detect up to 35 rhythms and morphologies, including AFib, bradycardia, tachycardia, and various sinus rhythms. PMcardio, clinically validated in over 25 studies, detects more than 50 ECG findings, including STEMI/OMI, reduced LVEF, and various arrhythmias, with reported 2x sensitivity for early STEMI detection and 98.3% accuracy for AFib.
PMcardio is designed for speed and simplicity, aiming to provide instant AI-powered ECG analysis. PMcardio offers email/help desk support, and its app includes in-app patient management recommendations based on clinical guidelines. Information regarding KardiaAI's specific learning curve or support quality beyond general customer support for Kardia devices is not explicitly detailed in the provided information.
KardiaAI focuses on analyzing ambulatory ECG rhythms to detect conditions like AFib, bradycardia, and tachycardia, and provides risk predictions for heart failure patients using EHR data. PMcardio offers a broader range of detection for over 50 cardiac conditions, including acute events like STEMI/OMI and pulmonary embolism, as well as chronic conditions like reduced LVEF and structural heart disease, and provides AI explainability with heatmaps. PMcardio also offers guideline-based treatment recommendations.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.